Functional proteins involved in regulation of intracellular Ca2+ for drug development: The extracellular calcium receptor and an innovative medical approach to control secondary hyperparathyroidism by calcimimetics

Journal of Pharmacological Sciences

Volumn 97, Issue 3, 2005, Pages 355-360

  Nagano, Nobuo ^a   Nemeth, Edward F ^b  

^a KIRIN BREWERY CO LTD   (Japan)

^b NPS Pharmaceuticals Incorporated   (Canada)

Author keywords

Calcimimetics; Calcium receptor; Extracellular calcium ion; Parathyroid hormone; Secondary hyperparathyroidism

Indexed keywords

CALCIMIMETIC AGENT; CALCIUM ION; CALCIUM RECEPTOR; CINACALCET; G PROTEIN COUPLED RECEPTOR; N [3 (2 CHLOROPHENYL)PROPYL] 1 (3 METHOXYPHENYL)ETHYLAMINE; PARATHYROID HORMONE; PHOSPHORUS; RECEPTOR; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D DERIVATIVE;

ABDOMINAL PAIN; ALLOSTERISM; CALCIUM BLOOD LEVEL; CALCIUM CELL LEVEL; CARDIOVASCULAR RISK; CELL SURFACE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONFERENCE PAPER; DIALYSIS; DIARRHEA; DISEASE ASSOCIATION; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; EXTRACELLULAR CALCIUM; GASTROINTESTINAL SYMPTOM; HORMONE ACTION; HORMONE BLOOD LEVEL; HORMONE INHIBITION; HORMONE RELEASE; HUMAN; HYPOCALCEMIA; KIDNEY FAILURE; NAUSEA; NONHUMAN; PARATHYROID CELL; PARATHYROID HYPERPLASIA; SECONDARY HYPERPARATHYROIDISM; VOMITING;

EID: 17144387916     PISSN: 13478613     EISSN: None     Source Type: Journal    
DOI: 10.1254/jphs.FMJ04007X6     Document Type: Conference Paper

References (35)

1. 2+ and other ions as extracellular (first) messengers. Physiol Rev. 1991;71:371-411.
2. 2+ and the regulation of secretion in parathyroid cells. FEBS Lett. 1986;203:15-19.
3. 2+-sensing receptor from bovine parathyroid. Nature. 1993; 366:575-580.
4. Nemeth EF. Calcium receptors as novel drug targets. In: Bilezikian JP, Raisz LG, Rodan GA, editors. Principles of bone biology. San Diego: Academic Press; 1996. p. 1019-1035.
5. Nemeth EF, Steffey ME, Hammerland LG, Hung BC, Van Wagenen BC, DelMar EG, et al. Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA. 1998;95:4040-4045.
6. 2+-sensing receptor. Trends Pharmacol Sci. 2000;21:401-407.
7. Kifor O, MacLeod RJ, Diaz R, Bai M, Yamaguchi T, Yao T, et al. Regulation of MAP kinese by calcium-sensing receptor in bovine parathyroid and CaR-transfected HEK293 cells. Am J Physiol Renal Physiol. 2001;280:F291-F302.
8. 2 action and arachidonic acid metabolism in calcium-mediated parathyroid hormone secretion. Endocrinology. 1992;130:1339-1344.
9. Bourdeau A, Moutahir M, Souberbielle JC, Bonnet P, Herviaux P, Sachs C, et al. Effects of lipoxygenase products of arachidonate metabolism on parathyroid hormone secretion. Endocrinology. 1994;135:1109-1112.
10. Quinn SJ, Bai M, Brown EM. pH sensing by the calcium-sensing receptor. J Biol Chem. 2004;279:37241-37249.
11. Conigrave AD, Mun HC, Delbridge L, Quinn SJ, Wilkinson M, Brown EM. L-Amino acids regulate parathyroid hormone secretion. J Biol Chem. 2004;279:38151-38159.
12. Riccardi D, Gamba G. The many roles of the calcium-sensing receptor in health and disease. Arch Med Res. 1999;30:436-448.
13. Quarles LD. Extracellualr calcium-sensing receptors in the parathyroid gland, kidney, and other tissues. Curr Opin Nephrol Hypertens. 2003;12:349-355.
14. Pollak MR, Seidman CE, Brown EM. Three inherited disorders of calcium sensing. Medicine. 1996;75:115-123.
15. Ho C, Conner DA, Pollak MR, Ladd DJ, Kifor O, Warren HB, et al. A mouse model of human familial hypocalciuric hypercalcemia and neonatal sever hyperparathyroidism. Nat Genet. 1995;11:389-394.
16. 2+-sensing receptor in primary and uremic secondary hyperparathyroidism. J Clin Endocrinol Metab. 1996;81:1598-1606.
17. Gogusev J, Duchambon P, Hory B, Giovannini M, Goureau Y, Sarfati E, et al. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int. 1997;51:328-336.
18. Pallais JC, Kifor O, Chen YB, Slovik D, Brown EM. Acquired hypocalciuruc hypercalcemia due to autoantibodies against the calcium-sensing receptor. N Eng J Med. 2004;351:362-369.
19. 2+ receptor/metabotropic glutamate chimeric receptors. Endocrinology. 2000;141:4156-4163.
20. Miedlich SU, Gama L, Seuwen K, Wolf RM, Breitwieser GE. Homology modeling of the transmembrane domain of the human calcium sensing receptor and localization of an allosteric binding site. J Biol Chem. 2004;279:7254-7263.
21. Murakami Y, Furuya Y, Wada M, Sakai T, Nagano N. Pharmacological properties of the calcimimetic compound NPS R-568 in vitro and in vivo. Clin Exp Nephrol. 2000;4:293-299.
22. 2+ receptor in rats. J Pharmacol Exp Ther. 1999;290:480-486.
23. Drüeke TB. The pathogenesis of parathyroid gland hyperplasia in chronic renal failure. Kidney Int. 1995;48:259-272.
24. Wada M, Furuya Y, Sakiyama J, Kobayashi N, Miyata S, Ishii H, et al. The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency: Control of parathyroid cell growth via a calcium receptor. J Clin Invest. 1997;100:2977-2983.
25. Wada M, Nagano N, Furuya Y, Chin J, Nemeth EF, Fox J. Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism. Kidney Int. 2000;57:50-58.
26. Chin J, Miller SC, Wada M, Nagano N, Nemeth EF, Fox J. Activation of the calcium receptor by a calcimimetic compound halts the progression of secondary hyperparathyroidism in uremic rats. J Am Soc Nephrol. 2000;11:903-911.
27. Antonsen JE, Sherrard DJ. Renal osteodystrophy: past and present. Semin Dialysis. 1996;9:296-302.
28. Wada M, Ishii H, Furuya Y, Fox J, Nemeth EF, Nagano N. NPS R-568 halts or reverses osteitis fibrosa in uremic rats. Kidney Int. 1998;53:448-453.
29. Ishi H, Wada M, Furuya Y, Nagano N, Nemeth EF, Fox J. Daily intermittent decreases in serum levels of parathyroid hormone have an anabolic-like action on the bones of uremic rats with low-turnover bone and osteomalacia. Bone. 2000;26:175-182.
30. Goodman WG, Hladik GA, Turner SA, Blaisdell PW, Goodkin DA, Liu W, et al. The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol. 2002;13: 1017-1024.
31. Quarles LD, Sherrard DJ, Adler S, Rosansky SJ, McCary LC, Liu W, et al. The calcimimetic AMG073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol. 2003;14:575-583.
32. Lindberg JS, Moe SM, Goodman WG, Coburn JW, Sprague SM, Liu W, et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium × phosphorus in secondary hyperparathyroidism. Kidney Int. 2003;63:248-254.
33. Block GA, Martin KJ, de Francisco ALM, Turner SA, Avram MM, Suranyi MG, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Eng J Med. 2004;350:1516-1525.
34. Malluche HH, Monier-Faugere MC, Wang G, Frazao JM, Charytan C, Caburn JW, et al. Cinacalcet HCl reduces bone turnover and bone marrow fibrosis in hemodialysis patients with secondary hyperparathyroidism (HPT). ERA-EDTA XLI Congress Abstract Book. 2004. p. 218-219.
35. Cunningham J, Chertow G, Goodman W, Danese M, Olson K, Klassen P, et al. The effect of cinacalcet HCl on parathyroidectomy, fracture, hospitalization, and mortality in dialysis subjects with secondary hyperparathyroidism. ERA-EDTA XLI Congress Abstract Book. 2004. p. 219.